Skip to main content

Evelo Biosciences, Inc.

EVLODelisted Dec 27, 2023
Industry
Pharmaceutical Preparations
SEC CIK
0001694665

Evelo Biosciences, Inc. was delisted on Dec 27, 2023; its insiders filed their last Form 4 on Nov 8, 2023; 29 institutions reported holding it in 13F filings for Q3 2023, worth $52.0M in total; no superinvestor held it.

13F holders, Q2 2023

Institutional positions in Evelo Biosciences, Inc. as of Jun 30, 2023. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works

Institutional holders
25
−14 vs. Q1 2023
Shares held
3.60M
−683.8K (−16.0%) vs. Q1 2023Converted for a 1-for-20 split
Total value
$11.3M
−$4.19M (−27.0%) vs. Q1 2023
New holders
1
7 more added
Sold out
15
11 more reduced

Compare with Q1 2023: new holders, sold out and not filed yet

Holders and value by quarter

Institutions reporting EVLO on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.

Institutional holdersQ2 2023: 25 institutions
Q1 2021: 62 institutionsQ2 2021: 66 institutionsQ3 2021: 64 institutionsQ4 2021: 66 institutionsQ1 2022: 68 institutionsQ2 2022: 46 institutionsQ3 2022: 41 institutionsQ4 2022: 44 institutionsQ1 2023: 39 institutionsQ2 2023: 25 institutionsQ3 2023: 29 institutionsQ4 2023: 2 institutionsQ1 2024: 0 institutionsQ2 2024: 0 institutionsQ3 2024: 0 institutionsQ4 2024: 0 institutionsQ1 2025: 0 institutionsQ2 2025: 0 institutionsQ3 2025: 0 institutionsQ4 2025: 0 institutionsQ1 2026: 0 institutionsQ2 2026: 0 institutions
Value heldQ2 2023: $11.3M
Q1 2021: $508.0MQ2 2021: $645.4MQ3 2021: $331.6MQ4 2021: $290.1MQ1 2022: $161.1MQ2 2022: $180.4MQ3 2022: $180.0MQ4 2022: $140.1MQ1 2023: $15.5MQ2 2023: $11.3MQ3 2023: $52.0MQ4 2023: $2.63KQ1 2024: $0Q2 2024: $0Q3 2024: $0Q4 2024: $0Q1 2025: $0Q2 2025: $0Q3 2025: $0Q4 2025: $0Q1 2026: $0Q2 2026: $0
Institutions holding EVLO and their total value by quarter
QuarterHoldersValue
Q2 20260$0
Q1 20260$0
Q4 20250$0
Q3 20250$0
Q2 20250$0
Q1 20250$0
Q4 20240$0
Q3 20240$0
Q2 20240$0
Q1 20240$0
Q4 20232$2.63K
Q3 202329$52.0M
Q2 202325$11.3M
Q1 202339$15.5M
Q4 202244$140.1M
Q3 202241$180.0M
Q2 202246$180.4M
Q1 202268$161.1M
Q4 202166$290.1M
Q3 202164$331.6M
Q2 202166$645.4M
Q1 202162$508.0M

Institutions, Q2 2023

Shares, value and share of portfolio for each institution holding Evelo Biosciences, Inc.; share changes are against Q1 2023.

Institutions holding EVLO in Q2 2023
InstitutionSharesValue% of portfolioChange in sharesAction
Flagship Pioneering Inc.2,521,369$8.19M0.37%00.0%UnchangedConverted for a 1-for-20 split
State of Michigan Retirement System203,536$661.5K0.00%00.0%UnchangedConverted for a 1-for-20 split
Vanguard Group Inc155,896$506.7K0.00%−2,523−1.6%ReducedConverted for a 1-for-20 split
HarbourVest Partners LLC153,175$497.8K0.14%00.0%UnchangedConverted for a 1-for-20 split
FMR LLC126,425$410.9K0.00%−683,429−84.4%ReducedConverted for a 1-for-20 split
Barclays PLC93,193$302.9K0.00%+92,649+17,026.3%AddedConverted for a 1-for-20 split
Credit Suisse AG180,520$180.5K0.00%00.0%UnchangedConverted for a 1-for-20 split
BlackRock Inc.53,539$174.0K0.00%−4,231−7.3%ReducedConverted for a 1-for-20 split
Alphabet Inc.53,024$172.3K0.01%00.0%UnchangedConverted for a 1-for-20 split
Geode Capital Management, LLC29,072$94.5K0.00%−1,362−4.5%ReducedConverted for a 1-for-20 split
Mayo Clinic22,577$73.4K0.08%−1,385−5.8%ReducedConverted for a 1-for-20 split
Morgan Stanley5,706$18.5K0.00%+2,775+94.7%AddedConverted for a 1-for-20 split
Tower Research Capital LLC (TRC)3,318$10.8K0.00%+1,702+105.3%AddedConverted for a 1-for-20 split
Group One Trading, L.P.1,018$3.31K0.00%+1,018New
UBS Group AG260$8450.00%−140−34.9%ReducedConverted for a 1-for-20 split
JPMorgan Chase & Co200$6500.00%+4+1.9%AddedConverted for a 1-for-20 split
Citigroup Inc95$3090.00%+33+52.1%AddedConverted for a 1-for-20 split
Advisor Group Holdings, Inc.75$2420.00%00.0%UnchangedConverted for a 1-for-20 split
China Universal Asset Management Co., Ltd.72$2340.00%−2−3.1%ReducedConverted for a 1-for-20 split
Larson Financial Group LLC36$1170.00%−1−2.6%ReducedConverted for a 1-for-20 split
Wells Fargo & Company21$680.00%+1+4.5%AddedConverted for a 1-for-20 split
Bank of America Corp15$490.00%−2,526−99.4%ReducedConverted for a 1-for-20 split
Royal Bank of Canada134$00.00%+133+19,042.9%AddedConverted for a 1-for-20 split
Daiwa Securities Group Inc.7$00.00%−1−10.3%ReducedConverted for a 1-for-20 split
Simplex Trading, LLC8$00.00%−65−89.1%ReducedConverted for a 1-for-20 split
CVI Holdings, LLC0$00.00%−42,029−100.0%Sold outConverted for a 1-for-20 split
Susquehanna International Group, LLP0$00.00%−9,205−100.0%Sold outConverted for a 1-for-20 split
State Street Corp0$00.00%−7,606−100.0%Sold outConverted for a 1-for-20 split
Trustees of Columbia University in the City of New York0$00.00%−5,693−100.0%Sold outConverted for a 1-for-20 split
Bridgeway Capital Management, LLC0$00.00%−5,265−100.0%Sold outConverted for a 1-for-20 split
Northern Trust Corp0$00.00%−4,717−100.0%Sold outConverted for a 1-for-20 split
Jefferies Financial Group Inc.0$00.00%−3,750−100.0%Sold outConverted for a 1-for-20 split
Millennium Management LLC0$00.00%−2,921−100.0%Sold outConverted for a 1-for-20 split
Goldman Sachs Group Inc0$00.00%−1,285−100.0%Sold outConverted for a 1-for-20 split
Virtu Financial LLC0$00.00%−1,217−100.0%Sold outConverted for a 1-for-20 split
Avantax Planning Partners, Inc.0$00.00%−750−100.0%Sold outConverted for a 1-for-20 split
Bank of New York Mellon Corp0$00.00%−658−100.0%Sold outConverted for a 1-for-20 split
Affinity Capital Advisors, LLC0$00.00%−530−100.0%Sold outConverted for a 1-for-20 split
BNP Paribas Arbitrage, SA0$00.00%−83−100.0%Sold outConverted for a 1-for-20 split
National Bank of Canada0$00.00%−5−100.0%Sold outConverted for a 1-for-20 split